Vivos Q1 Loss Hits $7.8M, Cash Dwindles to $2.1M as Delisting Looms
VVOS is trading near its 52-week low of $0.57 (1.8% above the low).
Summary
Vivos Therapeutics reported a substantial $7.8 million net loss for Q1 2026, with its cash balance dropping to a critical $2.1 million. This follows yesterday's 10-Q filing, which reiterated a 'going concern' warning and ongoing Nasdaq delisting risk due to non-compliance with minimum stockholders' equity. Despite a reported increase in revenue, the company's negative stockholders' equity and lack of new dentist enrollments highlight severe financial distress. The critically low cash position for an ~$8 million market cap company signals an urgent need for capital and a high risk of further dilution or bankruptcy.
At the time of this announcement, VVOS was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.57 to $7.95. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.